IKT vs. ALGS, DYAI, INAB, CRIS, ACHL, CYTH, QNCX, NKGN, INKT, and PLUR
Should you be buying Inhibikase Therapeutics stock or one of its competitors? The main competitors of Inhibikase Therapeutics include Aligos Therapeutics (ALGS), Dyadic International (DYAI), IN8bio (INAB), Curis (CRIS), Achilles Therapeutics (ACHL), Cyclo Therapeutics (CYTH), Quince Therapeutics (QNCX), NKGen Biotech (NKGN), MiNK Therapeutics (INKT), and Pluri (PLUR). These companies are all part of the "biological products, except diagnostic" industry.
Aligos Therapeutics (NASDAQ:ALGS) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, community ranking, earnings, profitability, dividends, media sentiment and analyst recommendations.
Aligos Therapeutics received 17 more outperform votes than Inhibikase Therapeutics when rated by MarketBeat users. However, 85.71% of users gave Inhibikase Therapeutics an outperform vote while only 62.16% of users gave Aligos Therapeutics an outperform vote.
Inhibikase Therapeutics has lower revenue, but higher earnings than Aligos Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.
Inhibikase Therapeutics has a consensus target price of $23.00, indicating a potential upside of 1,342.01%. Given Aligos Therapeutics' higher possible upside, analysts plainly believe Inhibikase Therapeutics is more favorable than Aligos Therapeutics.
Inhibikase Therapeutics has a net margin of 0.00% compared to Inhibikase Therapeutics' net margin of -783.72%. Inhibikase Therapeutics' return on equity of -144.16% beat Aligos Therapeutics' return on equity.
In the previous week, Aligos Therapeutics had 2 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 3 mentions for Aligos Therapeutics and 1 mentions for Inhibikase Therapeutics. Inhibikase Therapeutics' average media sentiment score of 0.88 beat Aligos Therapeutics' score of 0.00 indicating that Aligos Therapeutics is being referred to more favorably in the media.
60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 16.5% of Aligos Therapeutics shares are owned by insiders. Comparatively, 14.7% of Inhibikase Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Aligos Therapeutics has a beta of 2.19, suggesting that its stock price is 119% more volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500.
Summary
Aligos Therapeutics beats Inhibikase Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Inhibikase Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Inhibikase Therapeutics Competitors List
Related Companies and Tools
